RecruitingPhase 1NCT07388667

A Clinical Study of MK-4082 in Healthy Overweight Participants (MK-4082-002)

A Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MK-4082 in Healthy Overweight/Obese Participants

Sponsor

Merck Sharp & Dohme LLC

Enrollment

120 participants

Start Date

Mar 4, 2026

Study Type

INTERVENTIONAL

Conditions

Healthy

Summary

Researchers are looking for new weight loss medicines for people with higher body weight. The study medicine, MK-4082, is different from similar weight loss medicines because people take it as a pill instead of an injection. Before giving a study medicine to people with a health condition, researchers first do studies to find a safe dose level (amount) of the study medicine that can be used in future studies. The goals of this study are to learn about: * The safety of MK-4082 and if people tolerate it * What happens to different MK-4082 dose levels in a person's body over time

Eligibility

Min Age: 18 YearsMax Age: 60 Years

Inclusion Criteria2

Is in good health
Has body mass index (BMI) between 25 and 40 kg/m\^2, inclusive. Participants must weigh at least 60 kg

Exclusion Criteria2

has a history of previous surgical treatment for obesity (bariatric surgery, gastric banding, etc.) or any other gastrointestinal (GI) surgery that may induce malabsorption, history of bowel resection >20 cm, any malabsorption disorder, severe gastroparesis, or any GI procedure for weight loss (including LAP-BAND®), as well as clinically significant GI disorders (eg, peptic ulcers, severe gastroesophageal reflux disease)
has an individual or family history of medullary thyroid carcinoma or multiple endocrine neoplasia 2

Interested in this trial?

Get notified about updates and connect with the research team.